View Clinical Trial (Medical Research Study)

Carnitine Levels and Carnitine Supplementation in Type I Diabetes - NCT00351234-64108(Clinical Trial 308508)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Kansas City
State:  
MO
Zip Code: 64108
Conditions: Diabetes Mellitus, Type I - Hypoglycemia
Purpose: The purpose of this study is to determine whether type I diabetics with carnitine deficiency exhibit increased numbers of hypoglycemic (low blood sugars) events and if unrecognized hypoglycemia occurs during continuous 72-hour glucose monitoring. If they are determined to have unrecognized hypoglycemia, then oral carnitine supplementation will be given to those subjects and they will be reassessed for the number of hypoglycemic events in a 72-hour glucose monitoring.
Study summary: Hypoglycemia is a clinical marker of carnitine deficiency. Thus carnitine may compound the risk of hypoglycemia for children on insulin therapy. Currently, one of the limitations in the management of diabetes is hypoglycemia. The problem of hypoglycemia is of even greater significance in the pediatric population because children have smaller glycogen stores. In this study, we will determine if there is a group of children with increased frequency of hypoglycemia and carnitine deficiency. If there is a correlation from the initial 200 children, we will compare two groups of type I diabetic children between the ages of 7 to 21 years. We will take 20 children with the highest carnitine levels (found in a previous study) and 20 children with the lowest carnitine levels and perform continuous glucose monitoring for a 72-hour period. Those who have at least one episode of hypoglycemia will be asked to undergo repeat testing, after a 2-week period of oral carnitine supplementation. Supplementation will start at 50 mg/kg body weight for the first week and then increase to 100 mg/kg body weight the second week. Laboratory studies obtained at baseline include Hemoglobin A1c, carnitine panel, and lipid panel. These will be repeated prior to the second continuous glucose monitoring. Insulin doses will not be changed between glucose monitoring sessions. A comparison will be made between individuals with hypoglycemia, to see if the number of hypoglycemic events has decreased.
Criteria: Inclusion Criteria: - Diabetes Mellitus, Type I for greater than 2 years between the ages of 7 and 21 - currently on insulin replacement therapy Exclusion Criteria: - Patients with newly diagnosed Type I diabetes - Patients already taking L-carnitine - Patients who come to clinic without glucose monitors - Patients with known seizure disorders not including hypoglycemic seizures - Patients on metformin - Patients with compromised renal function.
Study is available at: The Children's Mercy Hospital
Kansas City, MO 64108
United States

Primary Contact:
Larry K Midyett, MD
Email: kmidyett@cmh.edu
Phone: 816-234-1660
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 21, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.